國立高雄大學圖資館 |

Language: English

Back

I. Design, synthesis, and biological...

Baryza, Jeremy L.

I. Design, synthesis, and biological evaluation of new analogs of bryostatin. II. Investigations into the mode of action of apoptolidin A.

Record Type:	Electronic resources : Monograph/item
Title/Author:	I. Design, synthesis, and biological evaluation of new analogs of bryostatin. II. Investigations into the mode of action of apoptolidin A.
Author:	Baryza, Jeremy L.
Description:	257 p.
Notes:	Adviser: Paul A. Wender.
Notes:	Source: Dissertation Abstracts International, Volume: 66-08, Section: B, page: 4223.
Contained By:	Dissertation Abstracts International66-08B.
Subject:	Chemistry, Organic.
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3186323
ISBN:	9780542285691

I. Design, synthesis, and biological evaluation of new analogs of bryostatin. II. Investigations into the mode of action of apoptolidin A.
Baryza, Jeremy L.

I. Design, synthesis, and biological evaluation of new analogs of bryostatin. II. Investigations into the mode of action of apoptolidin A. - 257 p.

Adviser: Paul A. Wender.

Thesis (Ph.D.)--Stanford University, 2005.

A practical synthesis of the most potent bryostatin analog reported to date has been achieved. This synthesis has also provided simple access to advanced materials that have been used in the preparation of additional analogs. Analogs of bryostatin with changes to the C-ring recognition domain have been prepared. A macrocyclic lactam analog bearing a modified pharmacophore was found to be inactive. The C20 position of bryostatin was identified as a non-pharmacophoric region of the molecule and analogs were prepared by a late stage-diversification strategy. These compounds bound potently to PKC, a known receptor for bryostatin, and retained functional activity. A receptor-docking model has been developed for analog design, producing a new hypothesis for the bryostatin-C1 domain interaction and successfully explains known SAR.

ISBN: 9780542285691Subjects--Topical Terms:

193634
Chemistry, Organic.

I. Design, synthesis, and biological evaluation of new analogs of bryostatin. II. Investigations into the mode of action of apoptolidin A.
LDR:03450nmm _2200313 _450 001 170760
005 20061228142238.5
008 090528s2005 eng d
020 $a 9780542285691
035 $a 00242790
040 $a UnM $c UnM
100 0 $a Baryza, Jeremy L. $3 244790
245 1 0 $a I. Design, synthesis, and biological evaluation of new analogs of bryostatin. II. Investigations into the mode of action of apoptolidin A.
300 $a 257 p.
500 $a Adviser: Paul A. Wender.
500 $a Source: Dissertation Abstracts International, Volume: 66-08, Section: B, page: 4223.
502 $a Thesis (Ph.D.)--Stanford University, 2005.
520 # $a A practical synthesis of the most potent bryostatin analog reported to date has been achieved. This synthesis has also provided simple access to advanced materials that have been used in the preparation of additional analogs. Analogs of bryostatin with changes to the C-ring recognition domain have been prepared. A macrocyclic lactam analog bearing a modified pharmacophore was found to be inactive. The C20 position of bryostatin was identified as a non-pharmacophoric region of the molecule and analogs were prepared by a late stage-diversification strategy. These compounds bound potently to PKC, a known receptor for bryostatin, and retained functional activity. A receptor-docking model has been developed for analog design, producing a new hypothesis for the bryostatin-C1 domain interaction and successfully explains known SAR.
520 # $a A series of functional assays have been developed to measure the ability of bryostatin analogs to activate PKC. These experiments demonstrate that the analogs have bryostatin-like effects and are more potent in some systems than the natural product. A-ring modifications result in selective activation of PKC isozymes. The use of fluorescent compounds has allowed observation of the uptake and distribution of analogs.
520 # $a Apoptolidin, a natural product with selective growth inhibition of cancer cell lines, has been investigated using new fluorescent biosensors, revealing that in H292 and HeLa cells apoptolidin induces arrest of the cell cycle in G1 phase.
520 # $a The bryostatins are a family of marine natural products with a unique combination of potency and activity. Bryostatin 1 has shown the ability to inhibit cancer cell growth, induce apoptosis, synergize with existing chemotherapeutics, reverse multi-drug resistance, stimulate immune function, improve memory and learning, and reduce amyloid plaque formation. Results from clinical trials indicate bryostatin 1 is active at doses of 25--50 mug/m 2. The natural abundance of bryostatin is too low to provide material for widespread use and the structural complexity of the natural product prevents its practical synthesis. Bryostatin is also unoptimized for therapeutic use. The design of molecules with bryostatin like function that can be produced in a practical fashion provides a reliable source of material and also provides a method of generating optimized therapeutics.
590 $a School code: 0212.
650 # 0 $a Chemistry, Organic. $3 193634
650 # 0 $a Health Sciences, Oncology. $3 226907
650 # 0 $a Chemistry, Pharmaceutical. $3 206042
690 $a 0490
690 $a 0491
690 $a 0992
710 0 # $a Stanford University. $3 212607
773 0 # $g 66-08B. $t Dissertation Abstracts International
790 $a 0212
790 1 0 $a Wender, Paul A., $e advisor
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://libsw.nuk.edu.tw:81/login?url=http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3186323 $z http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3186323